The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
11 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,768,000 in first-year total cost, median $245,625.
Most frequent study sections
- Clinical and Integrative Cardiovascular Sciences Study Section[CICS]3
- Cancer, Heart, and Sleep Epidemiology A Study Section[CHSA]1
- Cancer, Heart, and Sleep Epidemiology B Study Section[CHSB]1
- Cardiac Contractility, Hypertrophy, and Failure Study Section[CCHF]1
- Developmental Therapeutics Study Section[DT]1
Most frequent institutions
- UNIVERSITY OF PENNSYLVANIA3
- BARUCH S. BLUMBERG INSTITUTE1
- JOHNS HOPKINS UNIVERSITY1
- ROSWELL PARK CANCER INSTITUTE CORP1
- STATE UNIVERSITY OF NEW YORK AT BUFFALO1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Differentially methylated gene regions (DMRs) induced by doxorubicin in heart: significance and clinical application1R21HL156224-01A1 | GABRIELSON, KATHLEEN LOUISE | JOHNS HOPKINS UNIVERSITY, MD | $245,625 | MPPA |
| 2021 | Long Term Effects of Breast Cancer Therapy on Cardiac Remodeling and Function1R21HL157886-01 | KY, BONNIE | UNIVERSITY OF PENNSYLVANIA, PA | $243,750 | CHSA |
| 2021 | All-Extremity Exercise as a Novel Strategy for Optimizing Cardiovascular Function during Chemotherapy for Breast Cancer1R21HL152264-01A1 | CHRISTOU, DEMETRA | UNIVERSITY OF FLORIDA, FL | $228,750 | CICS |
| 2021 | Mitigating Long-term Cardiotoxicity with Nanoparticle Encapsulated Anthracyclines1R21HL157810-01 | AUNE, GREGORY J.YUSTEIN, JASON | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $218,685 | ZRG1 |
| 2021 | Prediction and Treatment for Cancer Immunotherapy Induced Myocarditis1R21HL154009-01A1 | PAN, HUA | UNIVERSITY OF SOUTH FLORIDA, FL | $186,875 | ZRG1 |
| 2020 | CCR5 inhibitors to enhance therapeutic response of breast cancer to DNA damaging agents1R21CA235139-01A1 | PESTELL, RICHARD G | BARUCH S. BLUMBERG INSTITUTE, PA | $382,756 | DT |
| 2020 | Biomarkers of oxidative stress, inflammation, and cardiac damage as markers of long-term radiation-induced cardiovascular outcomes in breast cancer1R21HL152149-01 | REDING, KERRYN W | UNIVERSITY OF WASHINGTON, WA | $291,393 | CICS |
| 2020 | Early Detection and Immunomodulation of PD-1 Inhibitor Induced Cardiotoxicity1R21HL154028-01 | POKHAREL, SARASWATI | ROSWELL PARK CANCER INSTITUTE CORP, NY | $258,790 | MIM |
| 2020 | Strategies in Cardiotoxicity Risk Reduction with Breast Cancer Therapy1R21HL150723-01 | KY, BONNIE | UNIVERSITY OF PENNSYLVANIA, PA | $257,238 | CHSB |
| 2020 | The Feasibility of a Biomarker Guided Strategy in Anthracycline Cardiotoxicity1R21HL152148-01 | KY, BONNIE | UNIVERSITY OF PENNSYLVANIA, PA | $254,763 | CICS |
| 2019 | Evaluation of myocardial targets to prevent anthracycline cardiotoxicity in children with Down Syndrome and Leukemia1R21CA245067-01 | BLANCO, JAVIER GUILLERMO | STATE UNIVERSITY OF NEW YORK AT BUFFALO, NY | $199,375 | CCHF |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.